Cover Image
Market Research Report

Asia Pacific Drug Discovery Market Forecast 2019-2027

Published by Inkwood Research Product code 609207
Published Content info 91 Pages
Delivery time: 2-3 business days
Price
Back to Top
Asia Pacific Drug Discovery Market Forecast 2019-2027
Published: August 12, 2019 Content info: 91 Pages
Description

KEY FINDINGS

The Asia Pacific drug discovery market is predicted to flourish with CAGR of 8.97% between the forecast period of 2019 and 2027. The Asia Pacific market is estimated to generate a revenue of $XX million by the end of 2027. As many multinational healthcare and pharmaceuticals companies are setting up their businesses in Asian countries, the region showcases a bright prospect for the drug discovery market.

MARKET INSIGHTS

The market analysis of the region is studied over emerging economies like China, Japan, South Korea, India, Australia, along with the rest of the Asia Pacific regional segment that includes other Asian countries. The Indian drug discovery market is driven primarily by the rising research efforts to discover new drugs from plants. The research institutions in India have made significant investments in drug discovery programs to bring together industries, national research laboratories, and academia. Also, the Government of India is taking efforts to make India a hub for end-to-end drug manufacturing. All these developments in the emerging economies of the Asia Pacific region are elevating the drug discovery market growth.

COMPETITIVE INSIGHTS

Some of the leading companies operating in the drug discovery market include Eli Lily, Johnson and Johnson, Glaxosmithkline LLC, F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim, among others. The high cost associated with research & development of new drugs together with government regulations is posing as entry-level barriers to new entrants in the market.

Table of Contents
Product Code: 13801

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
    • 3.2.3. BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
    • 3.2.4. SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
    • 3.2.5. CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST GROWING END USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. AGING POPULATION
    • 4.2.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.2.3. GROWING HEALTHCARE EXPENDITURE
    • 4.2.4. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. DELAY IN PRODUCT LAUNCHES
    • 4.3.2. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.3.3. SHIFT FROM BRANDED TO GENERIC DRUGS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
    • 4.4.2. INCREASING DEMAND FOR SPECIALTY MEDICINES
    • 4.4.3. RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
    • 4.5.2. STRINGENT GOVERNMENT REGULATIONS

5. MARKET BY TECHNOLOGY

  • 5.1. HIGH THROUGHPUT SCREENING
  • 5.2. BIOCHIPS
  • 5.3. BIOINFORMATICS
  • 5.4. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 5.5. COMBINATORIAL CHEMISTRY
  • 5.6. NANOTECHNOLOGY
  • 5.7. SPECTROSCOPY
  • 5.8. METABOLOMICS
  • 5.9. OTHER TECHNOLOGIES

6. MARKET BY DRUG TYPE

  • 6.1. SMALL MOLECULE DRUG
  • 6.2. BIOLOGIC DRUG

7. MARKET BY SERVICE

  • 7.1. DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
  • 7.2. CHEMICAL SERVICES
  • 7.3. BIOLOGICAL SERVICES
  • 7.4. OTHER PHARMACEUTICAL SERVICES

8. MARKET BY END USER

  • 8.1. RESEARCH INSTITUTES
  • 8.2. PHARMACEUTICAL COMPANIES
  • 8.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 8.4. OTHER END USER

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREATS OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
  • 9.2. COMPETITIVE RIVALRY
  • 9.3. VALUE CHAIN ANALYSIS
  • 9.4. PESTLE ANALYSIS
  • 9.5. REGULATORY FRAMEWORK
  • 9.6. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. ASIA PACIFIC
    • 10.1.1. CHINA
    • 10.1.2. INDIA
    • 10.1.3. JAPAN
    • 10.1.4. SOUTH KOREA
    • 10.1.5. AUSTRALIA
    • 10.1.6. REST OF ASIA PACIFIC

11. COMPANY PROFILES

  • 11.1. 3M COMPANY
  • 11.2. ANTARES PHARMA
  • 11.3. ASTRAZENECA PLC
  • 11.4. BAYER AG
  • 11.5. BECTON, DICKINSON & COMPANY (BD)
  • 11.6. BOEHRINGER INGELHEIM
  • 11.7. ELI LILY
  • 11.8. F. HOFFMANN-LA ROCHE LTD.
  • 11.9. GLAXOSMITHKLINE LLC
  • 11.10. JOHNSON AND JOHNSON
  • 11.11. MERCK & CO. INC.
  • 11.12. NOVARTIS
  • 11.13. PFIZER, INC.
  • 11.14. SANOFI

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • TABLE 2 ASIA PACIFIC DRUG DISCOVERY MARKET BY TECHNOLOGY, 2019-2027 ($ MILLION)
  • TABLE 3 ASIA PACIFIC HIGH THROUGHPUT SCREENING MARKET, 2019-2027 ($ MILLION)
  • TABLE 4 ASIA PACIFIC BIOCHIPS MARKET, 2019-2027 ($ MILLION)
  • TABLE 5 ASIA PACIFIC BIOINFORMATICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 6 ASIA PACIFIC PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 7 ASIA PACIFIC COMBINATORIAL CHEMISTRY MARKET, 2019-2027 ($ MILLION)
  • TABLE 8 ASIA PACIFIC NANOTECHNOLOGY MARKET, 2019-2027 ($ MILLION)
  • TABLE 9 ASIA PACIFIC SPECTROSCOPY MARKET, 2019-2027 ($ MILLION)
  • TABLE 10 ASIA PACIFIC METABOLOMICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 11 ASIA PACIFIC OTHER TECHNOLOGIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 12 ASIA PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)
  • TABLE 13 ASIA PACIFIC SMALL MOLECULE DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 14 ASIA PACIFIC BIOLOGIC DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 15 ASIA PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)
  • TABLE 16 ASIA PACIFIC DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 17 ASIA PACIFIC CHEMICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 18 ASIA PACIFIC BIOLOGICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 19 ASIA PACIFIC OTHER PHARMACEUTICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 20 ASIA PACIFIC DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)
  • TABLE 21 ASIA PACIFIC RESEARCH INSTITUTES MARKET, 2019-2027 ($ MILLION)
  • TABLE 22 ASIA PACIFIC PHARMACEUTICAL COMPANIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 23 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, 2019-2027 ($ MILLION)
  • TABLE 24 ASIA PACIFIC OTHER END USER MARKET, 2019-2027 ($ MILLION)
  • TABLE 25 ASIA PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 2 ASIA PACIFIC DRUG DISCOVERY MARKET SHARE BY TECHNOLOGY 2018 & 2027 (%)
  • FIGURE 3 ASIA PACIFIC DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 4 ASIA PACIFIC DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)
  • FIGURE 5 ASIA PACIFIC DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)
  • FIGURE 6 ASIA PACIFIC DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)
  • FIGURE 7 ASIA PACIFIC DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2019-2027 ($ MILLION)
  • FIGURE 8 ASIA PACIFIC DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)
  • FIGURE 9 ASIA PACIFIC DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)
  • FIGURE 10 ASIA PACIFIC DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)
  • FIGURE 11 ASIA PACIFIC DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)
  • FIGURE 12 ASIA PACIFIC DRUG DISCOVERY MARKET SHARE BY DRUG TYPE 2018 & 2027 (%)
  • FIGURE 13 ASIA PACIFIC DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)
  • FIGURE 14 ASIA PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)
  • FIGURE 15 ASIA PACIFIC DRUG DISCOVERY MARKET SHARE BY SERVICE 2018 & 2027 (%)
  • FIGURE 16 ASIA PACIFIC DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 17 ASIA PACIFIC DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 18 ASIA PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 19 ASIA PACIFIC DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 20 ASIA PACIFIC DRUG DISCOVERY MARKET SHARE BY END USER 2018 & 2027 (%)
  • FIGURE 21 ASIA PACIFIC DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)
  • FIGURE 22 ASIA PACIFIC DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)
  • FIGURE 23 ASIA PACIFIC DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)
  • FIGURE 24 ASIA PACIFIC DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 CHINA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 27 INDIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 28 JAPAN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 29 SOUTH KOREA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 30 AUSTRALIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 31 REST OF ASIA PACIFIC DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
Back to Top